Small molecule (PROTAC degrader) · Degrader of androgen receptor (AR) · developed by Arvinas
Bavdegalutamide is an orally available androgen receptor-targeted protein degrader using PROTAC technology. It binds the AR ligand binding domain and recruits E3 ligase to tag AR for ubiquitin-mediated proteasomal degradation, preventing AR-mediated signaling and proliferation in castration-resistant prostate cancer cells.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03888612 | Phase 1/2 | Prostate Cancer Metastatic | Completed | ARVN |
| NCT05177042 | Phase 1 | Prostate Cancer Metastatic | Completed | ARVN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Prostate Cancer Metastatic
Updated Oct 3, 2026. Something wrong or missing? Report it on the ARVN page.
See ARVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARVN catalysts and pipeline →